Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The American Society of Human Genetics (ASHG) honors Kay E. Davies with the William Allan Award

*** PRESS RELEASE ***

 

BETHESDA, MD – The American Society of Human Genetics (ASHG) has named Kay E. Davies, DPhil, Dr. Lee’s Professor of Anatomy, Department of Physiology, Anatomy and Genetics and Associate Head of the Medical Sciences Division; and Director of the Medical Research Council Functional Genomics Unit at the University of Oxford, the 2015 recipient of the annual William Allan Award.

The Allan Award, which recognizes a scientist for substantial and far-reaching scientific contributions to human genetics, was established in 1961 in memory of William Allan, MD (1881-1943), one of the first American physicians to conduct extensive research on human genetics and hereditary diseases. Dr. Davies will receive her award, which will include an engraved medal and monetary prize, on Friday, October 9, during ASHG’s 65th Annual Meeting in Baltimore. She will present her William Allan Award address immediately thereafter.

Dr. Davies led early research into Duchenne Muscular Dystrophy (DMD), a genetic disorder marked by muscle weakness that progresses rapidly. In the 1980s, her research group identified genetic markers that allow prenatal diagnosis and carrier status determination of DMD and mapped the gene coding for DMD to a specific location on the X chromosome. They also described the gene’s size and deletions in the DNA associated with disease, including a very large deletion of the gene coding for the protein dystrophin found in a patient with mild disease. Follow-up research showed that in mice, introducing the smaller dystrophin gene could prevent disease progression. These observations pioneered the development of dystrophin “minigenes” for the treatment of DMD in people.

Dr. Davies’ work also led to the characterization of the protein utrophin, a relative of dystrophin. Her group showed that, in mice, increasing utrophin levels could prevent disease. More recently, Dr. Davies has developed drugs that increase utrophin levels in mice and is pursuing these as an approach to treat DMD in humans. Unlike some existing therapeutics, which are effective only in a small number of DMD patients, this strategy would be applicable to all patients. 

Her laboratory also uses mouse models to study other neurogenetic diseases, such as schizophrenia and amyotrophic lateral sclerosis (ALS), with a focus on genes that affect the course of disease and clinical outcomes.

A longtime member of ASHG, Dr. Davies served on the Society’s Board of Directors from 2011-2013 and currently serves as Chair of its Nominating Committee. She has published 384 peer-reviewed papers, won numerous awards and delivered several special lectures at various institutions.  In 2012, she was awarded Honorary Membership of the Genetics Society (UK) in recognition of her contributions to the field.

* * *

About the American Society of Human Genetics (ASHG)

Founded in 1948, the American Society of Human Genetics is the primary professional membership organization for human genetics specialists worldwide. Its nearly 8,000 members include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses, and others with an interest in human genetics. The Society serves scientists, health professionals, and the public by providing forums to: (1) share research results through the ASHG Annual Meeting and in The American Journal of Human Genetics; (2) advance genetic research by advocating for research support; (3) educate current and future genetics professionals, health care providers, advocates, policymakers, educators, students, and the public about all aspects of human genetics; and (4) promote genetic services and support responsible social and scientific policies. For more information, visit: http://www.ashg.org.

Similar stories

Just over half of British Indians would take COVID vaccine

EDI News Outreach Postdoctoral Publication Research Riley Group News

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Lukas Krone to represent Oxford at the Global Young Scientists Summit

Awards and Honours EDI News Head of Department's News Students Vyazovskiy Group News

Congratulations are in order for Dr Lukas Krone who is one of just five University of Oxford researchers selected to attend the Global Young Scientists Summit 2021.

Two major BHF awards to Neil Herring pave the way to new treatments for heart attack patients

Awards and Honours Cardiac Theme Herring Group News

Associate Professor Neil Herring has been awarded a Senior Clinical Research Fellowship and a Project grant from the British Heart Foundation to further critical research into the mechanisms behind heart attacks and heart failure and potential drugs to combat them. Given the 50% reduction in research investment this year from the BHF due to the impact of COVID-19, Prof Herring is to be congratulated on these awards.

Pawel Swietach becomes Professor Pawel Swietach

Awards and Honours Head of Department's News

Congratulations are in order to Pawel Swietach on his conferral of the title of full Professor. Research in the Swietach Lab is driven by an interest in how biological processes are affected by chemical acidity.

MRC Senior Non-Clinical Fellowship awarded to Samira Lakhal-Littleton

Awards and Honours Cardiac Theme EDI News Lakhal-Littleton Group News

Congratulations are in order for Associate Professor Samira Lakhal-Littleton, who has been awarded a Senior Non-Clinical Fellowship by the Medical Research Council to further her lab's work exploring the implications of the cardiac hepcidin/ferroportin axis for the management of iron deficiency in heart failure.